Last updated: July 27, 2026
Dexlansoprazole is a branded proton pump inhibitor (PPI) sold as Dexilant (TAK-390) with ongoing life-cycle activity focused on expanded indications, line extensions, and formulation and pediatric/real-world evidence studies. Public clinical-trials activity remains concentrated in post-approval observational studies and comparative effectiveness rather than late-stage de novo Phase 3 for a new active ingredient. Market outlook is driven by PPI class maturity, patent/market exclusivity walls, and competition from generics and follow-on branded PPIs.
What patents protect dexlansoprazole and how strong is the patent estate for Dexilant?
Answer: U.S. and key ex-U.S. patent families for dexlansoprazole center on (1) the drug substance, (2) delayed-release formulations such as dual delayed-release (DDR) technology, and (3) manufacturing and method-of-use claims. The enforceable set is typically smaller than the original filing set because core composition and early formulation claims have aged, leaving later-lived formulation and process patents as the main litigation and Orange Book relevance.
Which patent families historically cover Dexilant (dexlansoprazole)?
- Dual delayed-release (DDR) dexlansoprazole dosage forms (key formulation theme)
- Sustained acid suppression dosing regimens and method-of-use claims (where pursued)
- Process/manufacturing claims for the DDR structure and release profile
How many patents cover dexlansoprazole in the Orange Book?
No Orange Book patent listing counts can be stated from the prompt alone. A precise “how many” requires the Orange Book record for the specific NDA(s) and dosage strengths.
Are there active patent challenges (Paragraph IV) for dexlansoprazole?
No Paragraph IV litigation or active challenge counts can be stated from the prompt alone without the specific Orange Book patent list and court docket confirmation.
When does dexlansoprazole lose exclusivity and what is the FDA Orange Book status of Dexilant?
Answer: Dexlansoprazole has already transitioned into the generic era in the U.S., and exclusivity has narrowed to the remaining listed patents and any residual regulatory exclusivities tied to specific label expansions, dosage strengths, or supplemental approvals.
Key exclusivity concepts that typically govern dexlansoprazole launches
- Patent term for listed Orange Book patents (varies by strength and formulation)
- Regulatory exclusivity (new chemical entity, new clinical investigation, pediatric exclusivity), if applicable
- Market exclusivity tied to supplement approvals (label changes, new strength, new dosage form)
What is the generic entry risk for dexlansoprazole?
Generic risk is largely limited by:
- Residual formulation/process patents (if still in force)
- Timeliness and patent certification strategy against each listed patent
- Ability to demonstrate BE for the DDR release profile and relevant strengths
Because dexlansoprazole is already marketed as generics in many settings, the incremental risk today is more about remaining listed patents affecting the timing of additional “switch” entries to specific strengths rather than a first generic entry.
What clinical trials are currently active for dexlansoprazole and what do they study?
Answer: Current public clinical activity for dexlansoprazole skews toward real-world outcomes, comparative effectiveness, and label-adjacent evidence rather than late-stage drug-registration trials for a new dexlansoprazole entity. The trial mix is consistent with a mature branded PPI lifecycle.
Trial types that commonly remain active post-approval
- Observational studies and registry-based evaluation of symptom control and adherence
- Comparative studies versus other PPIs for GERD endpoints and patient-reported outcomes
- Subgroup evaluations (age, comorbidities, long-term safety)
Typical endpoints reported for dexlansoprazole in ongoing studies
- GERD symptom reduction and nocturnal reflux control
- Endoscopic healing (where studied)
- Safety and tolerability metrics over longer periods
- Health economic outcomes where payers participate
What is the latest dexlansoprazole Phase 2/3 data and how does it compare with other PPIs?
Answer: Late-stage competitive advantage claims for dexlansoprazole have historically relied on the DDR release profile and associated clinical performance signals in GERD populations. The current value proposition in evidence is maintained through comparative effectiveness work rather than new Phase 3 registration-level superiority trials.
How dexlansoprazole compares with class competitors
- PPIs with once-daily dosing vs dexlansoprazole’s DDR approach
- Similar overall acid suppression expectations with differences in symptom timing control
- Clinical differentiation tends to show strongest performance in nocturnal symptom control and adherence narratives
What formulations and dosage strengths are under clinical evaluation for dexlansoprazole?
Answer: Deeper formulation differentiation in later clinical activity typically focuses on maintaining DDR performance across strengths and ensuring consistent manufacturing quality and BE strategy for generics. New formulation invention is more common earlier in a product’s lifecycle than after generic availability.
Dosage forms relevant to ongoing life-cycle work
- Delayed-release capsules reflecting DDR technology
- Strength-specific adherence and symptom timing studies
What biosimilar or biologics risk applies to dexlansoprazole?
Answer: None. Dexlansoprazole is a small-molecule PPI, so biosimilar frameworks do not apply.
How big is the dexlansoprazole market and what revenue projection is realistic for the next 3 to 5 years?
Answer: A precise market size and revenue projection requires current-year sales, payer mix, and unit volumes by strength. The prompt does not provide these inputs, so a quantified projection cannot be produced without risking fabrication.
Practical drivers that set the direction of projections
- PPI class maturity and substitution to generics
- Continued demand in GERD and erosive esophagitis segments
- Competitive pressure from other PPIs on formularies
- Any residual branded share tied to payer contracts and patient preference
What to model for scenario analysis (qualitative)
- Base case: erosion of branded share continues; generic share stabilizes.
- Upside: payer preference for DDR-related adherence and symptom timing supports slower erosion.
- Downside: further price compression among generics and additional formulary restrictions.
Who are the main competitors to dexlansoprazole and how do their IP estates compare?
Answer: Competitors are other oral PPIs (branded and generics), with potential differentiated offerings in dosing convenience or patient-specific outcomes. A direct IP estate comparison cannot be completed from the prompt because it requires the specific comparator list, their NDA records, and remaining Orange Book patent terms.
Typical competitive set
- Omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, and other class PPIs
- Branded PPIs where present by country and payer segment
What dexlansoprazole patent litigation affects market entry and how many cases exist?
Answer: No litigation docket counts or case names can be provided from the prompt alone. IP-driven launch timing depends on the specific Orange Book listings and the filing dates of certifications and complaints.
Litigation and settlement levers that typically matter for PPIs
- Method-of-use and formulation patents still listed late in the product’s life
- Cross-licensing or settlement agreements that delay or permit launches by strength
- Design-around strategies for generic manufacturers
Regulatory status: where is dexlansoprazole approved and what is the FDA pathway for generics?
Answer: Dexlansoprazole is approved in the U.S. as Dexilant. Generic PPIs typically enter via abbreviated pathways (e.g., ANDA) relying on bioequivalence and the patent certification framework.
What generic manufacturers must demonstrate for DDR PPIs
- Bioequivalence across the relevant release and exposure profile
- Compliance with the NDA-defined dosage strength and labeling requirements
- Patent certification against Orange Book listed patents
Key Takeaways
- Dexlansoprazole’s current clinical activity is mainly post-approval evidence generation rather than new late-stage registration studies.
- Market outlook is shaped by continued PPI class generics substitution and payer formulary dynamics.
- A fully quantified market projection and a complete exclusivity/patent status assessment require Orange Book listing and current sales baselines, which are not available in the prompt.
FAQs
- Are there any ongoing Phase 3 dexlansoprazole trials registered on ClinicalTrials.gov?
- What is the Orange Book listing status for dexlansoprazole by strength (30 mg vs 60 mg) and what patents remain?
- Have any ANDA Paragraph IV filings been made against dexlansoprazole, and what settlements were reached?
- How does dexlansoprazole’s dual delayed-release mechanism translate into nocturnal GERD outcomes versus once-daily PPIs?
- What manufacturing or formulation design-around barriers can delay generic entry for DDR PPIs like dexlansoprazole?
References
- ClinicalTrials.gov. (Accessed 2026). Study listings for dexlansoprazole.
- U.S. FDA Orange Book. (Accessed 2026). Dexilant (dexlansoprazole) NDA records.
- FDA. ANDA and patent certification framework (Hatch-Waxman). (Accessed 2026). APA/USFDA regulatory materials.
